Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Midostaurin

Protein Kinase Inhibitors

Enzyme Inhibitors

Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.

Novartis Pharmaceuticals

This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.

Adult patients (18 years or older) with the inclusion diagnosis, AML (ICD-10 C92.0), between 1.1.2013 - 30.6.2020 were followed from the index date (first ever record of the inclusion diagnosis) until the end of follow-up (30.6.2020), or death. This study did not involve any contacts to patients.

The study inclusion period was changed from 1.1.2013 - 30.6.2020 specified in the protocol to 1.1.2016 - 30.6.2020 due to lack of medication data from pre-2016.

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) With a Focus on Patients Treated With Rydapt (Midostaurin) in Helsinki and Uusimaa Hospital District

Number of patients initiating midostaurin treatment were reported.

Number of patients who received Midostaurin at induction and consolidation phases were reported.

Duration of Midostaurin at induction and consolidation phase were reported.

Median average dose intensity in midostaurin treatment were reported.

Most frequent comorbidities at the time of AML diagnosis were reported.

Number of patients at the time of diagnosis (All treated AML patients) were reported.

Number of AML patients receiving midostaurin consolidation treatment in inpatient or outpatient care (based on given prescriptions) were reported.

Estimate HCRU and related costs in different disease stages were reported.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)	NCT05488613	Acute Myeloid L...	Midostaurin	18 Years - 99 Years	Novartis
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)	NCT05488613	Acute Myeloid L...	Midostaurin	18 Years - 99 Years	Novartis

Spots Global Cancer Trial Database for healthcare resource utilization